Companies · Pharmaceuticals

Kv Pharmaceutical Co /De/

Chesterfield · Pharmaceuticals

Diligence memoA one-page analyst read on Kv Pharmaceutical Co /De/ — recommendation, valuation, rhythm, risks.
$526.0M
Total raised · real
5
Rounds
1242.3×
Latest step-up
Top 2%
Sector rank · raised
Series D+
Latest stage · inferred · Thu Jun 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

Kv Pharmaceutical Co /De/ looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.61× the median modeled value of Series D+ Pharmaceuticals companies in 2013–2015 (6 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.1 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Kv Pharmaceutical Co /De/ is one of 1613 Pharmaceuticals companies tracked from Chesterfield. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5B$5.0B$7.5B$10.0BSeries A · 2010-11-17 Raised $7.6M (real) Modeled valuation $234M (est)$7.6M$234MSeries A2010Series B · 2011-02-17 Raised $32M (real) Modeled valuation $1.1B (est)$32M$1.1BSeries B2011Series D+ · 2011-03-17 Raised $225M (real) Modeled valuation $7.9B (est)$225M$7.9BSeries D+2011Series D+ · 2012-06-05 Raised $210K (real) Modeled valuation $7.4M (est)$210K$7.4MSeries D+2012Series D+ · 2013-06-06 Raised $261M (real) Modeled valuation $9.2B (est)$261M$9.2BSeries D+2013+$32M+$225M+$210K+$261MCumulative $526M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$7.6M · 2010
Series B$32.3M · 2011
Series D+$225.0M · 2011no Series C on file
Series D+ extension$210K · 2012
Series D+ extension$260.9M · 2013

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$9.2B
Base estimate est.
$1.2B
Conservative case
$20.2B
Upside case
$2.2B
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $233.9M · 2010-11-172010Series B · modeled $1.1B · 2011-02-17Series D+ · modeled $7.9B · 2011-03-17Series D+ · modeled $7.4M · 2012-06-05Series D+ · modeled $9.2B · 2013-06-062013
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
71%
Survival probability
57% low · 79% high
1.35×/yr
Annual markup
1.51×/yr upside case
6.0 yr
Elapsed time used
13.1 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
8 mo
Avg between rounds
$206.1M/yr
Capital velocity
15.6 yr
On record since
2010
First round
5
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 65× above median
This company$526.0M
Sector median$8.1M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 2.3× above median
This company$260.9M
Sector median$111.8M
Modeled value — vs sector median (estimate, all stages) 121× above median
This company$9.2B
Sector median$76.1M

Raised more than 99% of sector peers (real $). Modeled value above 99% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 6.

This companyCohort peer
$100.0M$1.0B$10.0B$100.0B$100.0M$1.0BCapital raised (log)Clovis Oncology, Inc. · Series D+ Raised $358.3M · modeled $6.8B (est)Opko Health, Inc. · Series D+ Raised $206.0M · modeled $6.2B (est)Horizon Pharma, Inc. · Series D+ Raised $308.4M · modeled $5.3B (est)HLS Therapeutics Inc. · Series D+ Raised $142.8M · modeled $1.1B (est)Biotie Therapies Corp. · Series D+ Raised $149.8M · modeled $214.0M (est)Kv Pharmaceutical Co /De/ (this company) Raised $526.0M · modeled $9.2B (est)Kv Pharmaceutical Co /De/
CompanyStageRaised · realValue · estvs peer med.
Kv Pharmaceutical Co /De/ this companySeries D+$526.0M$9.2B1.61×
Clovis Oncology, Inc.Series D+$358.3M$6.8B1.18×
Opko Health, Inc.Series D+$206.0M$6.2B1.08×
Horizon Pharma, Inc.Series D+$308.4M$5.3B0.92×
HLS Therapeutics Inc.Series D+$142.8M$1.1B0.18×
Biotie Therapies Corp.Series D+$149.8M$214.0M0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$7.6M2010-11-17$34.3M$233.9M90%
Series B$32.3M2011-02-17$179.7M$1.1B90%
Series D+$225.0M2011-03-17$1.9B$7.9B90%
Series D+$210K2012-06-05$1.8M$7.4M90%
Series D+$260.9M2013-06-06$2.2B$9.2B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$7.6M2010-11-17
    • First recorded raise — entered as Series A.
  2. Series B$32.3M2011-02-17
    • Came back fast: 3 mo vs the ~13 mo sector norm.
    • Round 4.3× larger than the prior — scaling up.
  3. Series D+$225.0M2011-03-17
    • Came back fast: 1 mo vs the ~13 mo sector norm.
    • Round 7.0× larger than the prior — scaling up.
  4. Series D+$210K2012-06-05
    • Raised 15 mo later, in step with the ~13 mo sector norm.
    • Round 1071.4× smaller than the prior — bridge or down round.
  5. Series D+$260.9M2013-06-06
    • Raised 12 mo later, in step with the ~13 mo sector norm.
    • Round 1242.3× larger than the prior — scaling up.
Intelligence
2014 ~Q1
Modeled next raise · ~8mo cadence
$782.6M
Modeled next size est.range $508.7M$1.3B
1242.3×
Last step-up
$206.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ana I. Stancic1 other2010-11
Robert E. Baldini1 other2010-11
David D. Sidransky2010-11
David S. Hermelin2010-11
Eric J Haron2013-06
Gregory J Divis2013-06
Gregory J. Divis, Jr.2010-11
Gregory S. Bentley2010-11
Joe J McGinnis2013-06
Jonathan J Siegel2013-06
Joseph D. Lehrer2010-11
Mark A. Dow2010-11
Patrick J Christmas2013-06
Steve J Nielson2013-06
Thomas S. McHugh2010-11
Registry & provenance

Kv Pharmaceutical Co /De/ is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
57055
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Olema Pharmaceuticals, Inc.PharmaceuticalsSeries D+$527.4M$2.4Bsame sector · same stage
Recursion Pharmaceuticals, Inc.PharmaceuticalsSeries D+$478.3M$8.3Bsame sector · same stage
Lexicon Pharmaceuticals, Inc.PharmaceuticalsSeries D+$446.0M$374.2Msame sector · same stage
Precigen, Inc.PharmaceuticalsSeries D+$624.0M$405.3Msame sector · same stage
Galecto, Inc.PharmaceuticalsSeries D+$428.3M$2.0Bsame sector · same stage
Paragon Biosciences Emalex Capital, Inc.PharmaceuticalsSeries D+$376.8M$5.5Bsame sector · same stage
TrialSpark, Inc.PharmaceuticalsSeries D+$372.2M$4.1Bsame sector · same stage
Clovis Oncology, Inc.PharmaceuticalsSeries D+$358.3M$6.8Bsame sector · same stage
Frequently asked
How much funding has Kv Pharmaceutical Co /De/ raised?
Kv Pharmaceutical Co /De/ has raised approximately $526.0M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Kv Pharmaceutical Co /De/'s estimated valuation?
Provath's modeled valuation for Kv Pharmaceutical Co /De/ is approximately $9.2B (modeled range $1.2B–$20.2B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Kv Pharmaceutical Co /De/ at?
Kv Pharmaceutical Co /De/'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Thu Jun 06.
What does Kv Pharmaceutical Co /De/ do and where is it based?
Kv Pharmaceutical Co /De/ operates in the Pharmaceuticals sector, based in Chesterfield.
Explore related

See where Kv Pharmaceutical Co /De/ sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Kv Pharmaceutical Co /De/, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.